The mean quantitative asbestos exposure among both controls and patients with germline PVs was 2.7 f/mL-y compared to 21.7 f/mL-y among patients with MPM that did not have germline mutations in BAP1 or other cancer-predisposing genes [28]; thus, the mean quantitative asbestos exposure in MPM patients without germline PVs was 8.0-fold higher than in those with germline PVs. This evidence concerns the gene BAP1 and cancer.